BNA’s Health Care Daily Report™ sets the standard for reliable, high-intensity coverage of breaking health care news, covering all major legal, policy, industry, and consumer developments in a...
Aug. 29 — Republicans on the House Energy and Commerce Committee Aug. 29 questioned the FDA about its speed in approving generic drugs following concerns about the high price of EpiPens.
In an Aug. 29 letter, the lawmakers asked the Food and Drug Administration about the issues involved in bringing competitors to Mylan's allergy treatment EpiPen (epinephrine) onto the market. The letter was signed by full committee Chairman Fred Upton (R-Mich.), Health Subcommittee Chairman Joseph Pitts (R-Pa.) and Oversight and Investigations Subcommittee Chairman Tim Murphy (R-Pa.). Meanwhile, other House lawmakers also sent a letter to Mylan asking about the price increase of EpiPen.
Mylan has attracted scrutiny for increasing the treatment’s price 400 percent in nine years—EpiPen cost $57 for a single pen when the drugmaker bought it in 2007. The company is currently selling a set of two EpiPens for $600.
“In 2012, the Energy and Commerce Committee led the effort to pass the first generic drug user fee authorization (GDUFA) program,” the letter to the FDA said. “The goal of the legislation was to expedite the review of abbreviated new drug applications (ANDAs) and clear the backlog of applications at the agency. Improving the generic drug review process will promote competition and ultimately lower the cost of prescription drugs for America’s patients.”
The lawmakers said they “are concerned about the lack of generic competition in the epinephrine auto-injector market.”
Among other things, the lawmakers asked the FDA how many applications have been filed for a generic version of EpiPen, how many of those applications have been rejected or withdrawn and how many are pending.
They requested that the FDA respond by Sept. 9.
An FDA spokeswoman told Bloomberg BNA in an Aug. 29 e-mail that the agency “is authorized to review applications for new drugs for safety and effectiveness but does not have the authority to review or approve drug prices, which are set by manufacturers and distributors.”
“We are reviewing the questions posed in the letter and will respond directly to the Congressional members,” she said.
Reps. Jason Chaffetz (R-Utah) and Elijah E. Cummings (D-Md.) also sent a letter Aug. 29 to Heather Bresch, the chief executive officer of Mylan, requesting documents and communications regarding the increasing price of EpiPens.
Chaffetz is the chairman of the House Oversight and Government Reform Committee, and Cummings is its ranking member.
“Mylan has a virtual monopoly over the epinephrine auto-injector market,” the letter said. “While families and schools are struggling to keep up with your company’s unreasonable price increases, Mylan has profited richly from its pricing strategy.”
Chaffetz and Cummings requested documents related to the company’s revenues from sales of EpiPens since 2007, manufacturing costs and the amount of money the company receives from federal government health-care programs.
They asked Bresch to respond by Sept. 12.
Mylan didn't return a request for comment on the letter.
Josh Miller-Lewis, the deputy communications director for Sen. Bernie Sanders (I-Vt.), also told Bloomberg BNA in an e-mail that Sanders “is very concerned about the skyrocketing costs of prescription drugs and specifically EpiPens” and he “is considering next steps to stop the rising cost.”
To contact the reporter on this story: Bronwyn Mixter in Washington at email@example.com
To contact the editor responsible for this story: Brian Broderick at firstname.lastname@example.org
Copyright © 2016 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)